Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome
Language English Country England, Great Britain Media electronic
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
20630099
PubMed Central
PMC2914010
DOI
10.1186/1476-511x-9-71
PII: 1476-511X-9-71
Knihovny.cz E-resources
- MeSH
- Acute Coronary Syndrome blood drug therapy MeSH
- Atorvastatin MeSH
- Cholesterol blood MeSH
- Cholesterol, HDL blood MeSH
- Hypercholesterolemia drug therapy MeSH
- Heptanoic Acids administration & dosage therapeutic use MeSH
- Cholesterol, LDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipids blood MeSH
- Pyrroles administration & dosage therapeutic use MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage therapeutic use MeSH
- Triglycerides blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Atorvastatin MeSH
- Cholesterol MeSH
- Cholesterol, HDL MeSH
- Heptanoic Acids MeSH
- Cholesterol, LDL MeSH
- Lipids MeSH
- Pyrroles MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
- Triglycerides MeSH
BACKGROUND: Intensive statin therapy decreases mortality and incidence of coronary events in patients after acute coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during ACS. The immediate influence of lipid levels by high-dose statin therapy initiated at admission in ACS patients is, however, not clear. METHODS: We have analyzed a group of 114 patients with ACS (mean age 63.7; females 25.4%). Atorvastatin 80 mg was administered at admission and then once daily for the rest of hospitalization. The levels of total cholesterol (TC), LDL-cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) were measured at admission (D0), and then every morning of hospitalization (D1, D2). RESULTS: The mean entry values (D0) of TC, LDL, HDL and TG (in mmol/L) were 5.24, 3.26, 1.07 and 1.31, respectively. The therapy with atorvastatin 80 mg resulted in a decrease of TC levels in the first morning (D1) by 6.1% and in the second morning (D2) by 13.2% (p<0.001 for all comparisons with the entry value D0); LDL was decreased by 5.8% (D1) and 15.6% (D2) (p<0.001 vs. D0); the level of HDL was decreased by 7.5% (D1) and 12.1% (D2) (p<0.001 vs. D0). In contrast, the TG level was higher in the first morning (D1) by 20.6% and in the following morning (D2) by 25.5% (p<0.05 vs. D0). CONCLUSIONS: We have shown that intensive statin therapy started at admission in ACS patients has a highly significant, immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-term treatment of ACS patients.
See more in PubMed
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama. 2001;285:1711–1718. doi: 10.1001/jama.285.13.1711. PubMed DOI
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504. doi: 10.1056/NEJMoa040583. PubMed DOI
de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama. 2004;292:1307–1316. doi: 10.1001/jama.292.11.1307. PubMed DOI
Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814–1821. doi: 10.1001/archinte.166.17.1814. PubMed DOI
Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. Cmaj. 2008;178:576–584. PubMed PMC
Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, Martinkovicova L, Vojacek J. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Mol Cell Biochem. 2007;306:19–23. doi: 10.1007/s11010-007-9549-8. PubMed DOI
Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–616. doi: 10.1016/j.amjcard.2005.04.029. PubMed DOI
Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, Mates M, Kvapil M, Kettner J, Wiendl M. Fluvastatin in the first-line therapy of Acute Coronary Syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (The FACS-trial) Trials. 2010. PubMed PMC
Fyfe T, Baxter RH, Cochran KM, Booth EM. Plasma-lipid changes after myocardial infarction. Lancet. 1971;2:997–1001. doi: 10.1016/S0140-6736(71)90322-9. PubMed DOI
Sniderman AD, Teng B. Predictable changes in low density lipoprotein composition after acute myocardial infarction. Atherosclerosis. 1977;27:361–368. doi: 10.1016/0021-9150(77)90046-6. PubMed DOI
Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933–940. doi: 10.1016/0735-1097(93)90213-K. PubMed DOI
Fresco C, Maggioni AP, Signorini S, Merlini PA, Mocarelli P, Fabbri G, Lucci D, Tubaro M, Gattone M, Schweiger C. Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. Ital Heart J. 2002;3:587–592. PubMed
Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440–1445. doi: 10.1016/j.jacc.2007.11.075. PubMed DOI
Michelena HI, Osorio LA, Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol. 2005;101:111–114. doi: 10.1016/j.ijcard.2004.08.021. PubMed DOI
Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta. 2006;368:168–172. doi: 10.1016/j.cca.2005.12.040. PubMed DOI
Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36:617–621. doi: 10.1097/00005344-200011000-00011. PubMed DOI
Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol. 2003;26:472–476. doi: 10.1002/clc.4960261008. PubMed DOI PMC
Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–379. doi: 10.1161/hc2901.094094. PubMed DOI
Statins as first-line therapy for acute coronary syndrome?
